Junhemeng Biopharmaceutical raises Series C for recombinant protein drug platform
What's the deal? Junhemeng, a Chinese biotech company focused on recombinant protein drugs and synthetic biology, has closed a Series C funding round. Heda InvestmentDealroom has a profile for this one. Try Dealroom → and Hemeng Ventures co-led the round, with participation from Bencao CapitalDealroom has a profile for this one. Try Dealroom →, Chengshu InvestmentDealroom has a profile for this one. Try Dealroom →, Hongsheng CapitalDealroom has a profile for this one. Try Dealroom →, and Guangdian CapitalDealroom has a profile for this one. Try Dealroom →. The exact amount was not disclosed.
The company has built a recombinant protein drug development platform that spans high-efficiency expression systems, proprietary micro-denaturation purification technology, in vitro protein folding and self-assembly, and sustained-release formulations. Several of these technologies have already been industrialised.
Why now? Recombinant protein therapeutics represent a growing segment of the global biologics market, and China has been investing heavily in domestic biotech capabilities to reduce reliance on imported drugs. Junhemeng's platform — combining drug developability with novel manufacturing techniques — positions it to capitalise on rising demand for next-generation protein-based therapies.
What could go wrong? Drug development timelines are long and unpredictable. Turning a proprietary technology platform into commercially approved products requires clearing significant regulatory and clinical hurdles. Competition in the recombinant protein space is intensifying globally, with both established pharma players and well-funded startups vying for market share.
The signal: Junhemeng's focus on metabolism and medical aesthetics — two large, fast-growing end markets for recombinant proteins — helps explain why a mix of healthcare-specialist funds such as Bencao Capital and Chengshu Investment backed the round. The company's "breakout" growth stage suggests its platform is already translating into commercial traction, a milestone that separates it from earlier-stage peers still proving out their science.
